HeartBeam to Attend JP Morgan 2026 Healthcare Conference

Medical tech company focused on cardiac care insights to meet with investors and partners

Published on Feb. 25, 2026

Got story updates? Submit your updates here. ›

HeartBeam, Inc., a medical technology company dedicated to transforming cardiac care, announced that it will attend the JP Morgan 2026 Annual Healthcare Conference in San Francisco from January 12-15, 2026. CEO Robert Eno and CFO Timothy Cruickshank will be available for off-site meetings with investors and potential commercialization and co-development partners during the conference.

Why it matters

The conference attendance comes ahead of HeartBeam's planned limited U.S. commercial launch in Q1 2026 for its recently FDA-cleared 12-lead electrocardiogram synthesis software, which is designed to enable portable cardiac monitoring and assessment outside of medical facilities.

The details

Discussions at the conference are expected to focus on HeartBeam's recently announced 510(k) clearance from the FDA for its patented, cable-free 12-lead ECG synthesis software. This software is intended to allow for arrhythmia assessment and help redefine the future of cardiac health management by enabling physicians to identify trends and acute conditions remotely.

  • The JP Morgan 2026 Annual Healthcare Conference will take place from January 12-15, 2026 in San Francisco.
  • HeartBeam plans a limited U.S. commercial launch of its 12-lead ECG synthesis software in Q1 2026.

The players

HeartBeam, Inc.

A medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions through its patented 3D ECG technology and 12-lead ECG synthesis software.

Robert Eno

Chief Executive Officer of HeartBeam, Inc.

Timothy Cruickshank

Chief Financial Officer of HeartBeam, Inc.

Got photos? Submit your photos here. ›

What’s next

HeartBeam plans a limited U.S. commercial launch of its 12-lead ECG synthesis software in Q1 2026.

The takeaway

HeartBeam's attendance at the JP Morgan 2026 Healthcare Conference underscores its focus on transforming cardiac care through its innovative 3D ECG technology and 12-lead ECG synthesis software, which recently received FDA clearance and will soon be commercially available in the U.S.